Hainan Chengrui Biotechnology

Hainan Chengrui Biotechnology is a clinical-stage biopharmaceutical company specializing in the research and development of innovative peptide therapeutics for metabolic disorders. A subsidiary of Chengdu Chengrui Biotechnology, the company focuses on next-generation treatments for obesity, type 2 diabetes, and nonalcoholic steatohepatitis (NASH). Its lead program, CR001, is a long-acting GLP-1 receptor agonist designed for improved efficacy and patient compliance. The company's broader pipeline includes multi-target agonists, such as GLP-1/GIP dual agonists and GLP-1/GIP/GCG triple agonists, aimed at providing comprehensive metabolic control. Based in the Hainan Free Trade Port, the company leverages regional policies to streamline clinical trials and accelerate the commercialization of its metabolic pipeline.